Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A new modality for immunosuppression: targeting the JAK/STAT pathway.

× No keyword cloud information.

86 in total

1. Targeting Janus tyrosine kinase 3 (JAK3) with an inhibitor induces secretion of TGF-β by CD4+ T cells.

Authors: Marina Cetkovic-Cvrlje; Marin Olson; Ketaki Ghate
Journal: Cell Mol Immunol Date: 2012-06-25 Impact factor: 11.530

Review 2. Suppressors of cytokine signaling in health and disease.

Authors: Jane C Tan; Ralph Rabkin
Journal: Pediatr Nephrol Date: 2005-02-19 Impact factor: 3.714

3. Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog.

Authors: Titus J Boggon; Yiqun Li; Paul W Manley; Michael J Eck
Journal: Blood Date: 2005-04-14 Impact factor: 22.113

Review 4. The biological functions of the versatile transcription factors STAT3 and STAT5 and new strategies for their targeted inhibition.

Authors: Sylvane Desrivières; Christian Kunz; Itamar Barash; Vida Vafaizadeh; Corina Borghouts; Bernd Groner
Journal: J Mammary Gland Biol Neoplasia Date: 2006-01 Impact factor: 2.673

Review 5. Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond.

Authors: Alfonso Quintás-Cardama; Hagop Kantarjian; Jorge Cortes; Srdan Verstovsek
Journal: Nat Rev Drug Discov Date: 2011-02 Impact factor: 84.694

6. Benzoxathiol derivative BOT-4-one suppresses L540 lymphoma cell survival and proliferation via inhibition of JAK3/STAT3 signaling.

Authors: Byung Hak Kim; Yun Sook Min; Jung Sook Choi; Gyeong Hun Baeg; Young Soo Kim; Jong Wook Shin; Tae Yoon Kim; Sang Kyu Ye
Journal: Exp Mol Med Date: 2011-05-31 Impact factor: 8.718

Review 7. Beyond good and evil in the oral cavity: insights into host-microbe relationships derived from transcriptional profiling of gingival cells.

Authors: M Handfield; H V Baker; R J Lamont
Journal: J Dent Res Date: 2008-03 Impact factor: 6.116

A new modality for immunosuppression: targeting the JAK/STAT pathway.